A nurse is preparing to administer clozapine for the first time to a client who has schizophrenia

1. Lavretsky H. History of Schizophrenia as a Psychiatric Disorder. In: Mueser KT, Jeste DV, editors. Clinical Handbook of Schizophrenia. New York, New York: Guilford Press; 2008. pp. 3–12. [Google Scholar]

2. Crismon L, Argo TR, Buckley PF. Schizophrenia. In: DiPiro JT, Talbert RL, Yee GC, et al., editors. 1Pharmacotherapy: A Pathophysiologic Approach. 9th ed. New York, New York: McGraw-Hill; 2014. pp. 1019–1046. [Google Scholar]

3. Beck AT, Rector NA, Stolar N, Grant P. Schizophrenia: Cognitive Theory, Research, and Therapy. New York, New York: Guilford Press; 2009. Biological Contributions; pp. 30–61. [Google Scholar]

4. Schwartz JH, Javitch JA. Neurotransmitters. In: Kandel ER, Schwartz JH, Jessell TM, et al., editors. Principles of Neural Science. 5th ed. New York, New York: McGraw-Hill; 2013. pp. 289–305. [Google Scholar]

5. Stahl SM. Psychosis and Schizophrenia. In: Stahl SM, editor. Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 2nd ed. Cambridge, United Kingdom: Cambridge University Press; 2000. pp. 365–399. [Google Scholar]

6. Jentsch JD, Roth RH. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology. 1999;20(3):201–225. [PubMed] [Google Scholar]

7. Stahl SM, Morrissette DA, Citrome L, et al. “Meta-guidelines” for the management of patients with schizophrenia. CNS Spectr. 2013;18(3):150–162. [PubMed] [Google Scholar]

8. Siever LJ, Davis KL. The pathophysiology of schizophrenia disorders: perspectives from the spectrum. Am J Psychiatry. 2004;161(3):398–413. [PubMed] [Google Scholar]

9. McDonald C, Murphy KC. The new genetics of schizophrenia. Psychiatr Clin North Am. 2003;26(1):41–63. [PubMed] [Google Scholar]

10. Van Os J, Kapur S. Schizophrenia. Lancet. 2009;374(9690):635–645. [PubMed] [Google Scholar]

11. Wu E, Lizheng S, Birnbaum H, et al. Annual prevalence of diagnosed schizophrenia in the USA: a claims data analysis approach. Psychol Med. 2006;36(11):1535–1540. [PubMed] [Google Scholar]

12. American Psychiatric Association . Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Washington, DC: American Psychiatric Association; 2013. Schizophrenia and other psychotic disorders; pp. 89–122. [Google Scholar]

13. Satorius N, Jablensky A, Korten A, et al. Early manifestations and first-contact incidence of schizophrenia in different cultures. A preliminary report on the initial evaluation phase of the WHO collaborative study on determinants of outcomes of severe mental disorders. Psychol Med. 1968;16(4):909–928. [PubMed] [Google Scholar]

14. McGrath J, Saha S, Welham J, et al. A systematic review of the incidence of schizophrenia: the distribution of rates and the influence of sex, urbanicity, migrant status, and methodology. BMC Med. 2004;2:13. [PMC free article] [PubMed] [Google Scholar]

15. National Institute of Mental Health Schizophrenia 2009. Available at: http://www.nimh.nih.gov/health/publications/schizophrenia-easy-to-read/nimh-schizophrenia-quadfold.pdf. Accessed June 20, 2014.

16. Lehman AF, Lieberman JA, Dixon LB, et al. American Psychiatric Association Practice Guidelines; Work Group on Schizophrenia. Practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry. (2nd ed) 2004;161(suppl 2):1–56. [PubMed] [Google Scholar]

17. Dickerson FB, Lehman AF. Evidence-based psychotherapy for schizophrenia: 2011 update. J Nerv Ment Dis. 2011;199(8):520–526. [PubMed] [Google Scholar]

18. Lindenmayer JP, Liu-Seifert H, Kulkarni PM, et al. Medication non-adherence and treatment outcomes in patients with schizophrenia or schizoaffective disorder with suboptimal prior response. J Clin Psychiatry. 2009;70(7):990–996. [PubMed] [Google Scholar]

19. Morken G, Widen JH, Grawe RW. Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia. BMC Psychiatry. 2008;8:32. [PMC free article] [PubMed] [Google Scholar]

20. Rummel-Kluge C, Kissling W. Psychoeducation for patients with schizophrenia and their families. Exp Rev Neurother. 2008;8(7):1067–1077. [PubMed] [Google Scholar]

21. Castle DJ, Buckley PF. Schizophrenia. Oxford, United Kingdom: Oxford University Press; 2008. [Google Scholar]

22. Green AL, Canuso CM, Brenner MJ, Wojcik JD. Detection and management of comorbidity in patients with schizophrenia. Psychiatr Clin North Am. 2003;26(1):115–139. [PubMed] [Google Scholar]

23. Leucht S, Barnes TR, Kissling W, et al. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized controlled trials. Am J Psychiatry. 2003;160(7):1209–1222. [PubMed] [Google Scholar]

24. Argo TR, Crimson ML, Miller AL, et al. Schizophrenia Treatment Algorithms Texas Medication Algorithm Project procedural manual. Austin, Texas: Texas Department of State Health Services; 2008. Available at: http://www.dshs.state.tx.us/mhprograms/TIMA.shtm. Accessed June 20, 2014. [Google Scholar]

25. Moore TA, Buchanan RW, Buckley PF, et al. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. J Clin Psychiatry. 2007;68(11):1751–1762. [PubMed] [Google Scholar]

26. Raedler TJ. Cardiovascular aspects of antipsychotics: Curr Opin Psychiatry. 2010;23(6):574–581. [PubMed] [Google Scholar]

27. American Psychiatric Association Choosing wisely: five things physicians and patients should question. 2013. Available at: http://www.choosingwisely.org/wp-content/uploads/2013/09/102913_F64_46-APA-5things-List_Draft-5.pdf. Accessed June 20, 2014.

28. Kishimoto T, Robenzadeh A, Leucht C, et al. Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr Bull. 2014;40(1):192–213. [PMC free article] [PubMed] [Google Scholar]

29. Kishimoto T, Robenzadeh A, Leucht C, et al. Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. J Clin Psychiatry. 2013;74(10):957–965. [PubMed] [Google Scholar]

30. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45(9):789–796. [PubMed] [Google Scholar]

31. Spears NM, Leadbetter RA, Shutty MS. Clozapine treatment in polydipsia and intermittent hyponatremia. J Clin Psychiatry. 1996;57(3):123–128. [PubMed] [Google Scholar]

32. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of anti-psychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209–1223. [PubMed] [Google Scholar]

33. Kapur S, Mamo D. Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27(7):1081–1090. [PubMed] [Google Scholar]

34. Meltzer L, Li Z, Kaneda Y, Ichikawa J. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27(7):1159–1172. [PubMed] [Google Scholar]

35. Nyberg S, Eriksson B, Oxenstierna G, et al. Suggested minimal effective dose of risperidone based on PET measured D2 and 5-HT2A receptor occupancy in schizophrenic patients. Am J Psychiatry. 1999;156(6):869–875. [PubMed] [Google Scholar]

36. Haddad PM, Dursun SM. Neurological complications of psychiatric drugs: clinical features and management. Hum Psychopharmacol. 2008;23(suppl 1):15–26. [PubMed] [Google Scholar]

37. Pierre JM. Extrapyramidal symptoms with atypical antipsychotics: incidence, prevention and management. Drug Saf. 2005;28(3):191–208. [PubMed] [Google Scholar]

38. DeLeon A, Patel NC, Crismon ML. Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin Ther. 2004;26(5):649–666. [PubMed] [Google Scholar]

39. Monteleone P, Martiadis V, Maj M. Management of schizophrenia with obesity, metabolic and endocrinological disorders. Psychiatr Clin North Am. 2009;32(4):775–794. [PubMed] [Google Scholar]

40. Correll CU, Manu P, Olshanskiy, et al. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA. 2009;302(16):1765–1773. [PMC free article] [PubMed] [Google Scholar]

41. Weiden PJ, Ross R. Why do patients stop their antipsychotic medications? A guide for family and friends. J Psychiatr Pract. 2002;8(6):413–416. [PubMed] [Google Scholar]

42. Meyer JM. Cardiovascular illness and hyperlipidemia in patients with schizophrenia. In: Meyer JM, Nasarallah HA, editors. Medical Illness and Schizophrenia. Washington, D.C: American Psychiatric Press; 2003. pp. 53–80. [Google Scholar]

43. Mackin P. Cardiac side effects of psychiatric drugs. Hum Psychopharmacol. 2008;23(suppl 1):3–14. [PubMed] [Google Scholar]

44. Weinmann S, Read J, Aderhold V. Influence of antipsychotics on mortality in schizophrenia: systematic review. Schizophr Res. 2009;113(1):1–11. [PubMed] [Google Scholar]

45. Nasrallah HA. Metabolic findings from the CATIE trial and their relation to tolerability. CNS Spectr. 2006;11(suppl 7):32–39. [PubMed] [Google Scholar]

46. Caplan JP, Epstein LA, Quinn DK, et al. Neuropsychiatric effects of prescription drug abuse. Neuropsychol Rev. 2007;17(3):363–380. [PubMed] [Google Scholar]

47. Keefe RS, Bilder RM, Davis SM, et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Arch Gen Psychiatry. 2007;64(6):633–647. [PubMed] [Google Scholar]

48. Martin-Latry K, Goumy MP, Latry P, et al. Psychotropic drug use and the risk of heat-related hospitalization. Eur Psychiatry. 2007;22(6):335–338. [PubMed] [Google Scholar]

49. Li J, Tripathi RC, Tripathi BJ. Drug-induced ocular disorders. Drug Saf. 2008;31(2):127–141. [PubMed] [Google Scholar]

50. Fraunfelder FW. Twice-yearly exams unnecessary for patients taking quetiapine. Am J Ophthalmol. 2004;138(5):870–871. [PubMed] [Google Scholar]

51. Tsakiris P, Oelke M, Michel MC. Drug-induced urinary incontinence. Drugs Aging. 2008;25(7):541–549. [PubMed] [Google Scholar]

52. Knegtering H, van der Moolen AE, Castelein S, et al. What are the effects of antipsychotics on sexual dysfunctions and endocrine functioning? Psychoneuroendocrinology. 2003;28(suppl 2):109–123. [PubMed] [Google Scholar]

53. Hall RL, Smith AG, Edwards JG. Haematologic safety of antipsychotic drugs. Exp Opin Drug Saf. 2003;2(4):395–399. [PubMed] [Google Scholar]

54. Flanagan RJ, Dunk L. Haematological toxicity of drugs used in psychiatry. Hum Psychopharmacol. 2008;23(suppl 1):27–41. [PubMed] [Google Scholar]

55. Kapur S, Zipursky RB, Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry. 1999;156(2):286–293. [PubMed] [Google Scholar]

56. Lysaker PH, Buck KD. Is recovery from schizophrenia possible? An overview of concepts, evidence, and clinical implications. Prim Psychiatry. 2008;15(6):60–65. [Google Scholar]

57. Miller AL, Chiles JA, Chiles JK, et al. The TMAP schizophrenia algorithms. J Clin Psychiatry. 1999;60(10):649–657. [PubMed] [Google Scholar]

58. Spina E, de Leon J. Metabolic drug interactions with newer anti-psychotics: a comparative review. Basic Clin Pharmacol Toxicol. 2007;100(1):4–22. [PubMed] [Google Scholar]

59. Laursen TM, Munk-Olsen T, Vestergaard M. Life expectancy and cardiovascular mortality in persons with schizophrenia. Curr Opin Psychiatry. 2012;25(2):83–88. [PubMed] [Google Scholar]

Page 2

Comparative Risks of Weight Gain and Extrapyramidal Symptoms With Typical and Atypical Antipsychotic Agents2